Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod.

Abstract

Gorlin-Goltz syndrome, also referred to as naevoid basal cell carcinoma syndrome (NBCCS), is an autosomal dominant skin disease with complete penetrance and inconstancy of the four major findings: multiple naevoid basal cell carcinomas (BCCs), pits on palms and soles, skeletal abnormalities (for example, jaw cysts), and ectopic calcification. The treatment of multiple BCCs is still a matter of debate. We report three cases of multiple BCCs in Gorlin-Goltz syndrome treated with topical 5% imiquimod cream, an immune response modifier. Patients were successfully cleared of BCCs after treatment for 6-8 weeks. Histologically no apparent signs of BCC-persistence could be detected and no recurrences were detected during the 12 month follow up period.

• Authors: Eggert Stockfleth, Claas Ulrich, Axel Hauschild, Stephan Lischner, Thomas Meyer, Enno Christophers
• Journal: European journal of dermatology : EJD (Eur J Dermatol) 2002 Nov-Dec Vol. 12 Issue 6 Pg. 569-72 ISSN: 1167-1122 [Print] France
• PMID: 12459530 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aminoquinolines
• Imiquimod

Topics

• Administration, Topical
• Adult
• Aged
• Aminoquinolines (administration & dosage)
• Basal Cell Nevus Syndrome (drug therapy, pathology)
• Biopsy, Needle
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Face
• Female
• Follow-Up Studies
• Humans
• Imiquimod
• Immunohistochemistry
• Male
• Middle Aged
• Sampling Studies
• Skin Neoplasms (drug therapy, pathology)
• Treatment Outcome